ImmuCell Pauses Re-Tain Investment, Focuses on First Defense Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2025
0mins
Source: Benzinga
- FDA Incomplete Letter: ImmuCell received an Incomplete Letter from the FDA regarding its Re-Tain New Animal Drug Application, indicating that the contract manufacturer failed to address inspection deficiencies, which negatively impacts the company's future market access and product promotion.
- Investment Strategy Shift: Considering the impending expiration of its contract with the manufacturer in March 2026, ImmuCell has decided to pause further investment in Re-Tain and instead increase its investment in the First Defense franchise to adapt to market demand changes and enhance product competitiveness.
- Sales Force Expansion: The company plans to increase its First Defense field sales force by 50%, aiming to enhance market penetration and sales capabilities, thereby positioning itself more favorably in the competitive animal health market.
- Asset Impairment Expectation: Due to the strategic shift, ImmuCell anticipates recording a non-cash impairment write-down of approximately $2.3 million in the fourth quarter of 2025, which may impact the company's financial performance and investor confidence.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ICCC with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ICCC
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmuCell Reports $27.6M Sales in 2025, Significant Growth in Tri-Shield®
- Sales Overview: ImmuCell reported $7.6 million in sales for Q4 2025, a 1.6% decline from Q4 2024, yet total sales for the year reached $27.6 million, reflecting a 4.3% increase, indicating ongoing progress in rebuilding market position.
- Domestic Market Performance: Domestic sales hit $24.4 million in 2025, a 6.5% increase, showcasing robust growth in the U.S. market despite a 9.6% decline in international sales, highlighting the company's focus on domestic strength.
- Product Line Growth: Sales for the Tri-Shield® product line reached $19.9 million, up 26.5%, demonstrating strong demand and successful acquisition of new customers, particularly in the dairy and beef sectors.
- Strategic Shift: ImmuCell has decided to pause investments in Re-Tain®, anticipating a $2.9 million non-cash impairment write-down, while reallocating resources to First Defense® to enhance future production capacity and market share.
Continue Reading
ImmuCell Shifts Focus to First Defense Product Line Ahead of Q4 Sales Call
- Strategic Shift: ImmuCell announced on December 24, 2025, its strategic pivot from Re-Tain® to First Defense®, aiming to enhance cattle health and productivity, which is expected to strengthen its competitive position in the market.
- Financial Disclosure: The company plans to release its unaudited sales results for Q4 and the full year of 2025 after market close on January 8, 2026, providing investors with insights into its financial health.
- Investor Call: ImmuCell will host a conference call on January 9, 2026, at 9:00 AM ET to discuss its strategic shift and sales results, which is anticipated to attract investor interest and bolster market confidence.
- Future Plans: The company also intends to release its complete financial results on February 25, 2026, followed by another conference call on February 26, demonstrating its commitment to transparency and future growth prospects.
Continue Reading